Picture Twist Bioscience We Do DNA 650x100px

Document › Details

H. Lundbeck A/S. (2/7/18). "Press Release: Lundbeck Delivers Its Best Financial Results Following 10% Revenue Growth and 117% Growth in Net Profit". Valby.

	Organisation	H. Lundbeck A/S
	Group	Lundbeck (Group)
	Organisation 2	Otsuka Pharmaceutical Co., Ltd.
	Group	Otsuka (Group)
	Product	Abilify Maintena™
	Product 2	Trintellix® (formerly Brintellix®)
	Person	Götzsche, Anders (Lundbeck 201309 CFO)

Original document
accessed by [iito] on 2018-02-07

Record changed: 2023-06-05

Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x200px

More documents for Lundbeck (Group)

[1] Lundbeckfonden. (10/16/23). "Press Release: Venture Forces Invest Millions in New Type of Treatment for Particularly Aggressive Form of Cancer"....
[2] IO Biotech, Inc.. (8/7/23). "Press Release: IO Biotech, Inc. Announces $75 Million Private Placement Financing". New York, NY....
[3] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
[4] Lundbeckfonden. (4/4/22). "Press Release: Lundbeck Foundation Shifts into New Biotech Gear. New unit Raises Ambitions in Denmark – Lundbeckfonden BioCapital"....
[5] H. Lundbeck A/S. (11/29/21). "Press Release: Lundbeck Announces Changes to Executive Management". Valby....
[6] H. Lundbeck A/S. (10/14/21). "Press Release: Lundbeck Receives Exclusive Rights to APB-A1, an Innovative Phase I-ready Bio-therapeutic for the Treatment of Neuroimmune Diseases from AprilBio"....
[7] H. Lundbeck A/S. (8/5/20). "Press Release: Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia". Valby....
[8] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Announces Phase IIa Study Results of Lu AG06466 in Adults with Tourette Syndrome". Valby....
[9] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Reports Headline Results from Phase IIa AMBLED study of Foliglurax in Parkinson’s Disease". Valby....
[10] H. Lundbeck A/S. (10/22/19). "Press Release: Lundbeck Completes the Acquisition of Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention". Valby....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]